

PE anti-mouse CD25 Antibody

| | |
|--------------------------|--|
| Catalog# / Size | 102007 / 50 µg 102008 / 200 µg |
| Clone | PC61 |
| Regulatory Status | RUO |
| Other Names | IL-2Rα, Ly-43, p55, Tac |
| Isotype | Rat IgG1, λ |
| Description | CD25 is a 55 kD glycoprotein also known as the low affinity IL-2Rα, Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subsets, pre-B cells, and T regulatory cells. In association with CD122 (IL-2Rβ) and CD132 (common γ chain), CD25 forms the high affinity signaling IL-2 receptor. |

Product Details

| | |
|---|---|
| Verified Reactivity | Mouse |
| Antibody Type | Monoclonal |
| Host Species | Rat |
| Immunogen | IL-2-dependent cytolytic mouse T-cell clone B6.1 |
| Formulation | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide. |
| Preparation | The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. |
| Concentration | 0.2 mg/ml |
| Storage & Handling | The CD25 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| Application | FC - Quality tested |
| Recommended Usage | Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. |
| Excitation Laser | Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm) |
| Application Notes | Additional reported applications (for the relevant formats) include: immunoprecipitation ^{1,2} , <i>in vitro</i> blocking of IL-2 binding to low- and high-affinity receptors ¹⁻⁴ , growth inhibition of IL-2-dependent T-cell lines ¹⁻⁴ , <i>in vivo</i> depletion of CD25 ⁺ CD4 ⁺ Treg cells ^{5-8,10} , and immunohistochemical staining of acetone-fixed frozen sections ² . PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered. |
| Application References | <ol style="list-style-type: none"> 1. Lowenthal JW, <i>et al.</i> 1985. <i>Nature</i> 315:669. (IP, Block) 2. Ceredig R, <i>et al.</i> 1985. <i>Nature</i> 314:98. (IP, IHC, Block) 3. Lowenthal JW, <i>et al.</i> 1985. <i>J. Immunol.</i> 135:3988. (Block) 4. Moreau JL, <i>et al.</i> 1987. <i>Eur. J. Immunol.</i> 17:929. (Block) 5. Takahashi T, <i>et al.</i> 2000. <i>J. Exp. Med.</i> 192:303. (Deplete) 6. Onizuka S, <i>et al.</i> 1999. <i>Cancer Res.</i> 59:3128. (Deplete) 7. Lei TC, <i>et al.</i> 2005. <i>Blood</i> 105:4865. (Deplete) 8. Pasare C, <i>et al.</i> 2004. <i>Immunity</i> 21:733. (Deplete) 9. León-Ponte M, <i>et al.</i> 2007. <i>Blood</i> 109:3139. 10. Cao OW, <i>et al.</i> 2007. <i>Blood</i> doi:10.1182/blood-2007-02-073304. (Deplete) 11. Benson MJ, <i>et al.</i> 2007. <i>J. Exp. Med.</i> doi:10.1084/jem.20070719. 12. Liu F, <i>et al.</i> 2011. <i>Arch Toxicol.</i> 85:1383. PubMed |
| (PubMed link indicates BioLegend citation) | |

13. Anguela XM, *et al.* 2013. *Diabetes*. 62:551. [PubMed](#)

Product Citations

1. Madireddi S, *et al.* 2014. *J Exp Med*. 211:1433. [PubMed](#)
2. Jayachandran R, *et al.* 2019. *Immunity*. 50:152. [PubMed](#)
3. O'Malley G, *et al.* 2018. *Cancer Immunol Res*. 1.240277778. [PubMed](#)
4. Elong Ngono A, *et al.* 2020. *Cell Reports*. 1.330555556. [PubMed](#)
5. Merck E, *et al.* 2011. *J Immunol*. 187:110. [PubMed](#)
6. Yu HH, *et al.* 2021. *J Am Heart Assoc*. 10:e023077. [PubMed](#)
7. Hutter K, *et al.* 2022. *Front Immunol*. 13:967914. [PubMed](#)
8. Bruggemann TR, *et al.* 2022. *iScience*. 25:105185. [PubMed](#)
9. Li Q, *et al.* 2022. *Cell Rep*. 40:111308. [PubMed](#)
10. Castiello MC, *et al.* 2020. *J Allergy Clin Immunol*. . [PubMed](#)
11. Baptista AP *et al.* 2019. *Immunity*. 50(5):1188-1201 . [PubMed](#)
12. Delacher M, *et al.* 2021. *Immunity*. 54(4):702-720.e17. [PubMed](#)
13. Ibrahim M, *et al.* 2016. *J Evid Based Complementary Altern Med*. 21: 171 - 176. [PubMed](#)
14. Tyagi AM *et al.* 2018. *Immunity*. 49(6):1116-1131 . [PubMed](#)
15. Zhao B, *et al.* 2021. *Cell Reports*. 36(3):109401. [PubMed](#)
16. Imanishi T, *et al.* 2020. *Cell Reports*. 32(3):107911. [PubMed](#)
17. Sugimoto C, *et al.* 2022. *Elife*. 11:. [PubMed](#)
18. Guo Z, *et al.* 2016. *Nat Commun*. 7:10307. [PubMed](#)
19. Flaherty S, Reynolds J 2015. *J Vis Exp*. 98: 52739. [PubMed](#)
20. Liu YJ, *et al.* 2020. *Theranostics*. 10:5225. [PubMed](#)
21. Britton GJ *et al.* 2019. *Immunity*. 50(1):212-224 . [PubMed](#)
22. Singh K, *et al.* 2015. *Sci Rep*. 14:7767. [PubMed](#)
23. Feng H, *et al.* 2020. *J Dermatol*. 47:147. [PubMed](#)
24. Holvoet B, *et al.* 2015. *Stem Cell Reports*. 5: 1183-1195. [PubMed](#)
25. Xu L *et al.* 2017. *Immunity*. 47(3):538-551 . [PubMed](#)
26. Freitas JT, *et al.* 2021. *Pigment Cell Melanoma Res*. 34:1084. [PubMed](#)
27. Hutter K, *et al.* 2020. *FEBS J*. . [PubMed](#)
28. Ma W, *et al.* 2017. *Sci Rep*. . 10.1038/s41598-017-15661-6. [PubMed](#)
29. Diaz-Salazar C, *et al.* 2020. *Cell Rep*. 32:108186. [PubMed](#)
30. Becher J, *et al.* 2018. *Dev Cell*. 47:592. [PubMed](#)
31. Schoeler K, *et al.* 2019. *FEBS J*. 10.1111/febs.14934. [PubMed](#)
32. Yang J, *et al.* 2022. *Microbiome*. 10:149. [PubMed](#)
33. White C, *et al.* 2015. *J Immunol*. 194:697. [PubMed](#)
34. Lu X, *et al.* 2015. *J Immunol*. 194:2011. [PubMed](#)
35. Li Z, *et al.* 2018. *Front Immunol*. 9:347. [PubMed](#)
36. Chen Z, *et al.* 2021. *Front Cell Dev Biol*. 9:733308. [PubMed](#)
37. Zhang Q, *et al.* 2022. *Nat Commun*. 13:2406. [PubMed](#)
38. Germundson DL, *et al.* 2022. *Front Allergy*. 3:870513. [PubMed](#)
39. Su X, *et al.* 2022. *J Transl Med*. 20:378. [PubMed](#)
40. Anger-Góra N, *et al.* 2021. *Oncol Lett*. 22:582. [PubMed](#)
41. Yan J, *et al.* 2020. *Cell Rep*. 107820:31. [PubMed](#)
42. Galle-Treger L, *et al.* 2016. *Nat Commun*. 7:13202. [PubMed](#)
43. Chou T, *et al.* 2016. *Nat Commun*. 7:11904. [PubMed](#)
44. Kondo M, *et al.* 2016. *J Immunol*. 196: 563 - 572. [PubMed](#)
45. Sendler M, *et al.* 2020. *Gastroenterology*. 158:253. [PubMed](#)
46. Simula L *et al.* 2018. *Cell reports*. 25(11):3059-3073 . [PubMed](#)
47. Zhou J, *et al.* 2019. *Nat Commun*. 10:2427. [PubMed](#)
48. Li Y, *et al.* 2021. *Cell Death Dis*. 12:1001. [PubMed](#)
49. Biton J, *et al.* 2016. *J Immunol*. 197: 1708 - 1719. [PubMed](#)
50. Timilshina M, *et al.* 2017. *PLoS One*. 10.1371/journal.pone.0168942. [PubMed](#)
51. Yang BH, *et al.* 2020. *Cell Reports*. 27(12):3629-3645.e6.. [PubMed](#)
52. Tong D, *et al.* 2020. *Protein Cell*. 0.533333333. [PubMed](#)
53. Zhai X, *et al.* 2021. *Sci Adv*. 7:eabk0490. [PubMed](#)
54. Gao X, *et al.* 2022. *Front Immunol*. 13:799331. [PubMed](#)
55. Takenori Inomata, Jing Hua, Antonio Di Zazzo 2016. *Sci Rep*. 6:39924. [PubMed](#)
56. Yuan X, *et al.* 2017. *Elife*. 6:e29540. [PubMed](#)
57. Dahlgren MW *et al.* 2019. *Immunity*. 50(3):707-722 . [PubMed](#)
58. Feng D, *et al.* 2022. *Nat Commun*. 13:5554. [PubMed](#)
59. Yi H, *et al.* 2021. *Front Immunol*. 12:719189. [PubMed](#)
60. Orlanski S, *et al.* 2016. *Proc Natl Acad Sci U S A*. 113: 5018-5023. [PubMed](#)
61. Verma K, *et al.* 2017. *PLoS One*. 10.1371/journal.pone.0183828. [PubMed](#)
62. Schuler F, *et al.* 2017. *Nat Commun*. . 10.1038/s41467-017-01850-4. [PubMed](#)
63. Draijer C, *et al.* 2018. *Sci Rep*. 8:5105. [PubMed](#)
64. Tanaka Y, *et al.* 2017. *J Immunol*. 199:4016. [PubMed](#)
65. Wen J, *et al.* 2020. *Cell Rep*. 31:107566. [PubMed](#)
66. Wells AC *et al.* 2017. *eLife*. 6 pii: e26398. [PubMed](#)
67. Cantor DJ *et al.* 2019. *Cell reports*. 26(1):108-118 . [PubMed](#)
68. Xu JL, *et al.* 2022. *Front Pharmacol*. 13:911663. [PubMed](#)
69. Hoechst B, *et al.* 2016. *J Immunol*. 195:1517-1523. [PubMed](#)
70. Sun Y, *et al.* 2020. *J Immunol*. 205:2649. [PubMed](#)
71. Charlton J, *et al.* 2015. *PLoS One*. 10:119200. [PubMed](#)
72. Sun Y, *et al.* 2022. *iScience*. 25:104846. [PubMed](#)
73. Wang X, *et al.* 2022. *Elife*. 11:. [PubMed](#)
74. Liu X, *et al.* 2021. *Adv Sci (Weinh)*. 8:e2100233. [PubMed](#)
75. Timilshina M, *et al.* 2020. *Cell Reports*. 27(10):2948-2961.e7.. [PubMed](#)
76. Wang N, *et al.* 2020. *Front Immunol*. 1.765972222. [PubMed](#)

77. Hsu HP, *et al.* 2021. *J Biol Chem.* 296:100419. [PubMed](#)
 78. Olguin J, *et al.* 2015. *Microbes Infect.* 17: 586-595. [PubMed](#)
 79. Hsieh WC, *et al.* 2018. *Nat Commun.* 9:463. [PubMed](#)
 80. Chen YH, *et al.* 2022. *Arthritis Res Ther.* 24:27. [PubMed](#)

RRID AB_312856 (BioLegend Cat. No. 102007)
 AB_312857 (BioLegend Cat. No. 102008)

Antigen Details

| | |
|---------------------------|--|
| Structure | Forms high affinity IL-2R with IL-2R β (CD122) and IL-2R γ (CD132), 55 kD |
| Distribution | Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells |
| Function | IL-2 receptor |
| Ligand/Receptor | IL-2 |
| Cell Type | B cells, T cells, Thymocytes, Tregs |
| Biology Area | Immunology |
| Molecular Family | CD Molecules, Cytokine/Chemokine Receptors |
| Antigen References | <ol style="list-style-type: none"> 1. Taniguchi T, <i>et al.</i> 1993. <i>Cell</i> 73:5-8. 2. Waldmann TA. 1991. <i>J Biol Chem.</i> 266:2681-4. 3. Read S, <i>et al.</i> 2000. <i>J Exp Med.</i> 192:295-302. 4. Lowenthal JW, <i>et al.</i> 1985. <i>J Immunol.</i> 135:3988-94. |

Gene ID [16184](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD25, Biotin anti-mouse CD25, FITC anti-mouse CD25, PE anti-mouse CD25, PE/Cyanine5 anti-mouse CD25, Purified anti-mouse CD25, PE/Cyanine7 anti-mouse CD25, Alexa Fluor® 488 anti-mouse CD25, Alexa Fluor® 647 anti-mouse CD25, Pacific Blue™ anti-mouse CD25, Alexa Fluor® 700 anti-mouse CD25, APC/Cyanine7 anti-mouse CD25, PerCP/Cyanine5.5 anti-mouse CD25, PerCP anti-mouse CD25, Brilliant Violet 421™ anti-mouse CD25, Brilliant Violet 605™ anti-mouse CD25, Brilliant Violet 650™ anti-mouse CD25, Ultra-LEAF™ Purified anti-mouse CD25, Brilliant Violet 510™ anti-mouse CD25, PE/Dazzle™ 594 anti-mouse CD25, Brilliant Violet 711™ anti-mouse CD25, Brilliant Violet 785™ anti-mouse CD25, Alexa Fluor® 594 anti-mouse CD25, APC/Fire™ 750 anti-mouse CD25, TotalSeq™-A0097 anti-mouse CD25, KIRAVIA Blue 520™ anti-mouse CD25, TotalSeq™-B0097 anti-mouse CD25, TotalSeq™-C0097 anti-mouse CD25, Spark NIR™ 685 anti-mouse CD25 Antibody, PE/Fire™ 640 anti-mouse CD25, Spark YG™ 581 anti-mouse CD25, APC/Fire™ 810 anti-mouse CD25

Product Data



Con A-stimulated (3 days) BALB/c mouse splenocytes stained with PE

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587